| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
electroCore, Inc.$6.09
-0.21 (-3.26%)
F 17Pipeline Score MedTech · Clinical
Market Cap
55.33 M
EPS
-1.81
P/E Ratio
-
Value Trade
1.29 M
SEC Financials
Q1 2026Dilution Risk
Revenue
9.58 M
Operating CF
-3.01 M
Total Assets
15.48 M
Total Liabilities
21.17 M
Equity
-5.69 M
D/E Ratio
12,345
6.38 %
Week
7.41 %
1 Month
10.61 %
3 Month
44.37 %
6 Month
-72.38 %
5 Year
-97.53 %
All Time
Cash Data
Cash Position
8.83 M
Monthly Burn
1.00 M
Runway
6.1 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
37.06 K
52 Week Range
4.16 - 8.64
% held by Insiders
33.63 %
% held by Institutions
10.28 %
Enterprise Value
55.99 M
Total Shares
8.30 M
Short %
7.49 %
Float Shares
4.91 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F17
Pipeline Score $1M
Pipeline ValueValuation Signal
1
Drugs Scored0.0x
rNPV / MCap Top 16%
Micro Cap (rank 768 of 913)
Percentile RankelectroCore, Inc. has significant pipeline risk (17/100), with $18M risk-adjusted pipeline value, led by GammaCore in Chronic Cluster Headache (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GammaCore Unknown | Chronic Cluster Headache | Phase 2 | NCT01701245 | 12% | $18M | COMPLETED | 97 | - | - | Oct 1, 2014 | - | Apr 25, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TAC-STIM | mood enhancement, task performance, learning | — | 2025-12-02 | enhances mood, task performance, and learning | TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen Read More | |
TAC-STIM | mood enhancement, task performance, learning | — | 2025-12-02 | enhances mood, task performance, and learning | TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen Read More | |
TAC-STIM | mood enhancement, task performance, learning | — | 2025-12-02 | enhances mood, task performance, and learning | TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ECOR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ECOR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ECOR▼ -3.3%today
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
electroCore, Inc. announced that it will report its financial results for the second quarter ending June 30, 2026, on August 6, 2026. The company will host a webinar at 4:30 PM EDT to discuss these results and address investor questions. electroCore focuses on bioelectronic technologies aimed at improving health and quality of life.
Read more →ECORNew Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
electroCore, Inc. has published a peer-reviewed review article comparing auricular and cervical vagus nerve stimulation methods. The article discusses their anatomical differences, mechanisms of action, and clinical evidence. It emphasizes the growing support for cervical vagus nerve stimulation as a validated approach and outlines future research opportunities in the field of bioelectronic medicine.
Read more →ECORelectroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
electroCore, Inc. will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026. The company's Interim President and CFO, Joshua Lev, will present and conduct one-on-one meetings with investors. This event highlights electroCore's commitment to engaging with investors and promoting its bioelectronic health technologies.
Read more →ECORFrontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery
electroCore, Inc. announced that a review article on cervical non-invasive vagus nerve stimulation (nVNS) has been accepted for publication in Frontiers in Neuroscience. Authored by a team of experts, the article consolidates evidence supporting the effectiveness of nVNS in activating vagal pathways without surgery. This publication aims to address skepticism regarding non-invasive vagal activation and reinforces the clinical validation of cervical nVNS.
Read more →ECOR▼ -8.7%on this news
electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
electroCore, Inc. will present at the Planet MicroCap Las Vegas 2026 event, scheduled for June 17-18, 2026. Interim President and CFO Joshua Lev will lead the presentation and conduct one-on-one investor meetings. The event aims to connect public companies with investors, highlighting electroCore's advancements in bioelectronic medicine.
Read more →ECOR▼ -5.6%on this news
electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia
electroCore, Inc. announced the publication of a study in JAMA Network Open, demonstrating the effectiveness of the Quell device in reducing pain for fibromyalgia patients undergoing outpatient physical therapy. The study involved 384 participants and showed significant improvements in pain and fatigue levels. The results indicate that Quell may serve as a beneficial non-drug treatment option for fibromyalgia.
Read more →ECORelectroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
electroCore, Inc. will present at the LD Micro Invitational XVI Conference on May 18, 2026. The event will take place at the Luxe Sunset Boulevard hotel in Los Angeles, where Interim President and CFO Joshua Lev will deliver a presentation and conduct one-on-one meetings. This engagement highlights the company's focus on bioelectronic medicine and wellness.
Read more →ECORelectroCore Announces First Quarter 2026 Financial Results First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net lo
electroCore, Inc. announced its financial results for Q1 2026, reporting net sales of $9.6 million, a 43% increase compared to the previous year. The company experienced a net loss of $5.3 million, which includes costs related to leadership transitions. Despite these challenges, gross profit margins improved to 87%, highlighting operational advancements. The company reaffirmed its full-year 2026 revenue growth guidance of approximately 30% over 2025, driven by ongoing sales increases in their prescription and wellness product lines.
Read more →ECOR▲ +5.9%on this news
electroCore TAC-STIM™ Named National Semifinalist in National Safety Council Work to Zero Challenge
electroCore, Inc. announced that its TAC-STIM product has been named a national semifinalist in the 2026 Work to Zero Safety Innovation Challenge. This initiative by the National Safety Council aims to identify technologies that can mitigate workplace fatigue, a significant safety risk. TAC-STIM is designed to enhance decision-making and performance in high-demand environments, particularly for military personnel.
Read more →ECORelectroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026
electroCore, Inc. will report its financial results for Q1 2026 on May 6, 2026. A webinar will be held at 4:30 PM EDT for management to discuss the results and answer investor questions. The company specializes in bioelectronic medicine, focusing on non-invasive technologies for chronic pain and wellness.
Read more →ECORelectroCore to Present at the Market Movers Investor Summit on May 5, 2026
electroCore, Inc. will present at the Market Movers Investor Summit on May 5, 2026, in New York City. Interim President and CFO Joshua Lev will lead the presentation and engage in one-on-one meetings. The summit aims to connect company executives with investors, featuring various programming elements including keynote sessions and networking opportunities.
Read more →ECORelectroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation
electroCore, Inc. announced its participation in the documentary 'Hacking the Vagus Nerve,' which explores the vagus nerve's role in health. The film features electroCore's technologies, including gammaCore for migraines and Truvaga Plus for stress management. As interest in vagus nerve stimulation grows, electroCore aims to advance its therapeutic applications.
Read more →ECOR▼ -7.5%on this news
electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference
electroCore, Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. Interim President Joshua Lev will present at 2:15 pm ET and engage in one-on-one meetings with investors. This event highlights the company's focus on advancing bioelectronic technologies for health improvement.
Read more →ECORelectroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD
electroCore, Inc. has announced the enrollment of the first eight patients in a clinical study evaluating the safety and effectiveness of its gammaCore non-invasive vagus nerve stimulation device for PTSD. The study, conducted by Acacia Clinics and the Vagus Nerve Society, aims to enroll up to 40 participants over a 12-week period. Key endpoints include assessing treatment-related adverse events and changes in PTSD symptom scores.
Read more →ECOR▲ +9.5%on this newsshared move
electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD
electroCore, Inc. announced the publication of a study in Frontiers in Neuroscience, demonstrating the benefits of adjunctive non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD). The post-hoc analysis of 35 patients showed significant reductions in symptom burden across cognitive, affective, and somatic domains. This research adds to the existing literature on the therapeutic potential of nVNS.
Read more →ECOR▲ +6.9%on this news· ran to +25% by day 3shared move
electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
electroCore, Inc. has announced the hiring of Seth Abrams as VP of Sales and Michael Fox as COO, effective April 1 and April 13, 2026, respectively. Both executives will receive restricted stock units as part of their compensation, aligning with NASDAQ Listing Rule 5635(c)(4). The company aims to improve health through innovative bioelectronic technologies.
Read more →ECORelectroCore Expands Intellectual Property Portfolio
electroCore, Inc. announced the issuance of two new U.S. patents, enhancing its intellectual property portfolio in non-invasive vagus nerve stimulation technology. The patents cover innovative methods for vagus nerve modulation and remote patient monitoring. This expansion underscores electroCore's commitment to innovation and positions it strongly in the market for next-generation therapies.
Read more →ECOR▼ -5%on this news
electroCore Announces Full Year 2025 Financial Results and Organizational Changes Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our
electroCore announced its financial results for the full year 2025, reporting record net sales of $32.0 million, a 27% increase from 2024, driven by growth in the U.S. prescription business and general wellness sales. The company anticipates continued growth with a revenue guidance of approximately 30% for 2026. Key organizational changes include the retirement of CEO Dan Goldberger, with Joshua Lev appointed as interim President. Despite the positive sales growth, the company recorded a higher net loss compared to the previous year.
Read more →ECORelectroCore to Participate at the 38th Annual Roth Conference
electroCore, Inc. announced its participation in the 38th Annual Roth Conference, scheduled from March 22-24 in Laguna Niguel, California. The Chief Financial Officer, Joshua Lev, will conduct one-on-one meetings with interested investors during the event. This conference is significant for small-cap companies, providing a platform for management interaction and presentations to a broad array of investors. electroCore, known for its bioelectronic medicine technologies, aims to enhance health and quality of life through innovative solutions.
Read more →ECORelectroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026
electroCore, Inc. has announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on March 19, 2026. A webinar will be held at 4:30 PM EDT for management to review the results and answer investor questions. The company focuses on bioelectronic technologies aimed at improving health and quality of life.
Read more →ECOR▲ +10.2%on this news
Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)
electroCore, Inc. announced a new research initiative in collaboration with Acacia Clinics and the Vagus Nerve Society to study the effectiveness of gammaCore Sapphire for treating PTSD symptoms. The study aims to assess safety and efficacy over a 12-week period, enrolling up to 40 participants. This initiative highlights the potential of non-invasive vagus nerve stimulation as a treatment option.
Read more →ECORelectroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million
electroCore, Inc. has provided preliminary financial guidance indicating a projected revenue of $31.8 to $32.0 million for the full year 2025, representing a 26% increase from 2024. The fourth quarter is expected to show a 30% growth compared to the same quarter in 2024. However, the company’s cash position has decreased, raising concerns about future financial stability.
Read more →ECORelectroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8-$32.0 Million Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2
electroCore, Inc. has provided a preliminary business update indicating a projected record revenue for the full year 2025, estimated at approximately $31.8 to $32.0 million, reflecting a growth of around 26% from 2024. The company also anticipates revenue of about $9.0 to $9.2 million for the fourth quarter, marking a significant increase of approximately 30% compared to the same period in the previous year. As of the end of 2025, electroCore reported a cash balance of about $11.6 million. Detailed operational updates will be provided during the upcoming earnings call.
Read more →ECORTAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen
electroCore, Inc. announced a peer-reviewed study demonstrating that its TAC-STIM device enhances mood, task performance, and learning among active-duty U.S. Air Force personnel. The findings, presented at the AHFE2025 Conference, indicate the device's effectiveness in high-stress military environments, positioning it as a valuable tool for military and civilian applications. The study builds on previous research, emphasizing TAC-STIM's role in operational readiness and cognitive augmentation.
Read more →ECORelectroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
electroCore, Inc. will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025. The event will be held in New York at The Westin NY Grand Central Hotel, where management will conduct one-on-one meetings with investors. The company focuses on non-invasive bioelectronic technologies to improve health and wellness.
Read more →ECOR▲ +23.2%on this newsshared move
electroCore Announces Third Quarter 2025 Financial Results
electroCore, Inc. reported a 33% increase in net sales for Q3 2025, totaling $8.7 million. The company attributed this growth to strong prescription sales, particularly in the Veteran Affairs market. Despite the positive sales performance, electroCore experienced a net loss of $3.4 million, which was higher than the previous year's loss. The company has raised its revenue guidance for the full year 2025.
Read more →ECORelectroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025
electroCore, Inc. announced it will report its financial results for Q3 2025 on November 5, 2025. The company will host a webinar at 4:30 PM EST to discuss these results and answer investor questions. electroCore specializes in bioelectronic technologies aimed at improving health and wellness.
Read more →ECORelectroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
electroCore, Inc. announced the appointment of Jennifer Hayes as Vice President of Human Resources, effective October 6, 2025. In connection with her employment, the company granted her 10,000 restricted stock units (RSUs) under NASDAQ Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on her continued employment.
Read more →ECORgammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
electroCore, Inc. announced a peer-reviewed study showing that gammaCore non-invasive vagus nerve stimulation (nVNS) effectively reduces persistent symptoms of mild traumatic brain injury (mTBI). The study found significant improvements in patients treated with nVNS alongside standard care, with benefits observed regardless of the time since injury. No adverse events related to the device were reported.
Read more →ECORelectroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium
electroCore, Inc. announced that its gammaCore Sapphire device has received long-term reimbursement approval from RIZIV/INAMI in Belgium, effective October 1, 2025. This policy will cover treatment for cluster headaches, based on strong clinical evidence. The approval is expected to improve access for patients and reflects the growing recognition of non-invasive therapies.
Read more →ECOR▲ +5%on this news
electroCore’s Truvaga™ Plus Named “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards
electroCore, Inc. announced that its Truvaga Plus device has been awarded 'Best Relaxation Gadget' in Esquire's 2025 Sleep Awards. The recognition highlights the device's effectiveness in reducing stress and promoting better sleep through vagus nerve stimulation. The award is seen as validation for the product's benefits in the wellness market.
Read more →ECORelectroCore Announces Departure of Peter Cuneo from the Board of Directors and Elects Thomas J. Errico, MD as Chairman of the Board
electroCore, Inc. announced the departure of Peter Cuneo from its Board of Directors, with Thomas J. Errico, MD, elected as the new Chairman. Cuneo will remain as a strategic advisor. Errico, a co-founder of the company, is expected to provide valuable leadership and stewardship moving forward.
Read more →ECORelectroCore Partners with iHeartRadio and Former New York Jets Star Linebacker Greg Buttle to Champion Better Sleep and Stress Relief
electroCore has partnered with former NFL linebacker Greg Buttle to promote Truvaga Plus, a handheld vagus nerve stimulation device aimed at enhancing sleep and stress relief. Buttle emphasizes the importance of good sleep for performance, sharing his positive experience with the device. The partnership will include radio and digital campaigns to raise awareness about stress management and wellness.
Read more →ECORelectroCore Appoints Elena Bonfiglioli to Board of Directors ROCKAWAY, N.J.
electroCore, Inc. has appointed Elena Bonfiglioli to its Board of Directors, effective September 2, 2025, following the retirement of Peter Cuneo. Bonfiglioli is a seasoned healthcare executive with over twenty years of experience, currently serving at Microsoft and holding multiple board positions. She aims to leverage her background to enhance market growth and promote electroCore’s drug-free solutions for chronic pain management. The company's mission focuses on improving health through innovative bioelectronic technologies.
Read more →ECORelectroCore to Participate at H.C. Wainwright Global Investment Conference
electroCore, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference set for September 9, 2025. Management will conduct one-on-one meetings with potential investors throughout the event. This participation is aimed at enhancing investor relations and increasing awareness of the company's bioelectronic medicine solutions. electroCore specializes in non-invasive treatments for chronic pain and overall wellness.
Read more →ECORelectroCore Names Kelly Benning, Accomplished Healthcare Executive, as SVP of Truvaga
electroCore, Inc. has appointed Kelly Benning as the Senior Vice President of Truvaga, effective July 21, 2025. With extensive experience in digital health and AI technologies, Benning will lead the company's consumer wellness division. She aims to enhance electroCore's commitment to empowering consumers in their health journeys through innovative and accessible solutions. CEO Dan Goldberger expressed confidence in her ability to advance the company's direct-to-consumer strategy, indicating her importance to electroCore's growth initiatives.
Read more →ECORelectroCore Announces Second Quarter 2025 Financial Results Net sales of $7.4 million increased 20% vs. Q2'2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash
electroCore, Inc. announced strong financial results for Q2 2025, marking a 20% increase in net sales compared to Q2 2024, and a 22% increase year-to-date. The company reported cash equivalents and securities totaling $7.4 million. While the second quarter showed decreased cash usage, the company faced a net loss increase to $3.7 million. Additionally, it completed the acquisition of NeuroMetrix ahead of schedule, reinforcing its presence in the bioelectronic technology market.
Read more →ECOR▼ -5.4%on this news· ran to -36% by day 3shared move
electroCore Appoints James C. Theofilos to the Board of Directors
electroCore, Inc. announced the appointment of James C. Theofilos to its Board of Directors, effective August 1, 2025. Theofilos, who has experience leading finance initiatives at Microsoft, expressed excitement about leveraging his skills to enhance the company's strategic growth and drive shareholder value. His background in healthcare finance is expected to contribute positively to electroCore and support its innovative bioelectronic solutions for chronic pain management.
Read more →ECORelectroCore to Announce Second Quarter June 30, 2025 Financial Results on Wednesday, August 6, 2025
electroCore, Inc. has announced that it will report its financial results for the second quarter ending June 30, 2025, on August 6, 2025. Following the announcement, the company will host a webinar at 4:30 PM EDT to discuss the results and answer investor questions. electroCore is focused on innovative bioelectronic technologies for health and wellness, including its gammaCore and Quell products for chronic pain management.
Read more →ECORelectroCore to Participate in Upcoming Investor Conferences
electroCore, Inc. will participate in two upcoming investor conferences, the Needham 10th Annual Virtual MedTech and Diagnostics Conference and the Canaccord Genuity 45th Annual Growth Conference. Management plans to host one-on-one meetings during both events to engage with investors. This participation underscores the company's commitment to maintaining visibility and fostering relationships in the investment community.
Read more →ECORelectroCore Announces First Quarter 2025 Financial Results First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. ("NeuroMetrix"); first quart
electroCore, Inc. has announced its financial results for the first quarter of 2025, reporting net sales of $6.7 million, a 23% increase compared to the same period in 2024. The company has also successfully closed the acquisition of NeuroMetrix, enhancing its bioelectronic technology offerings. Although gross margins were maintained, general and administrative expenses rose due to seasonal costs and acquisition-related charges. Overall, electroCore improved its revenue growth and narrowed its operational loss despite some rise in overall expenses.
Read more →ECOR▼ -9.5%on this newsshared move
electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies Addition of Quell Platform Broadens electroCore's Bioelectron
electroCore, Inc. has completed its merger with NeuroMetrix, enhancing its position in non-invasive bioelectronic technologies. This acquisition adds the Quell Fibromyalgia solution to electroCore's product line, promising to expand its addressable market in chronic pain and wellness. The transaction includes a cash payment and contingent value rights for NeuroMetrix shareholders. However, it brings potential integration challenges and market risks that could impact financial performance.
Read more →ECORelectroCore’s Truvaga™ Now Works with the Apple Health app
electroCore, Inc. announced that its Truvaga Plus device now integrates with the Apple Health app, allowing users to better manage their health data. Truvaga Plus is designed to stimulate the vagus nerve for stress relief, improved sleep, and enhanced mental clarity. Users can track their feelings over time using the app's features. Despite potential future challenges, this integration aims to support long-term customer wellness and engagement.
Read more →ECORelectroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025
electroCore, Inc. announced it will release its financial results for the first quarter ending March 31, 2025, on May 7, 2025. After the market closes, management will conduct a webinar at 4:30 PM EST to discuss the results and answer questions from investors. This event highlights the company's commitment to keeping stakeholders informed about its financial performance.
Read more →ECORelectroCore to Participate at the Planet MicroCap Showcase
electroCore, Inc. has announced its participation in the Planet MicroCap Showcase, scheduled for April 23-24, 2025, at the Paris Hotel & Casino in Las Vegas. Dan Goldberger, the CEO, will host a group presentation and conduct one-on-one meetings with investors. This event highlights the company's commitment to its bioelectronic medicine and wellness technology, specifically non-invasive vagus nerve stimulation. Interested investors are encouraged to reach out to schedule meetings with the management.
Read more →ECOR▼ -11.3%on this news· ran to -22% by day 3
electroCore Named One of The Americas’ Fastest Growing Companies by the Financial Times
electroCore, Inc. has been recognized by the Financial Times as one of 'The Americas’ Fastest Growing Companies 2025', debuting at number 125 overall. The ranking reflects the company's significant compound annual revenue growth from 2020 to 2023 and highlights its position among 29 healthcare & life sciences firms. electroCore is noted for its innovative bioelectronic medicine solutions targeting pain management and overall well-being. This recognition validates the company's efforts towards commercialization and technological advancement in the medical devices sector.
Read more →ECOR▼ -7.5%on this newsshared move
electroCore to Participate at the Needham Virtual Healthcare Conference
electroCore, Inc. announced its participation in the Needham Virtual Healthcare Conference scheduled for April 10, 2025. CEO Dan Goldberger and CFO Joshua Lev will present a group session and engage in one-on-one meetings with investors. The event underscores electroCore's commitment to transparency and investor relations within the bioelectronic medicine sector. This conference offers a platform for discussing the company's advancements in non-invasive vagus nerve stimulation technology.
Read more →ECORelectroCore Extends VA Contract for Five Years
electroCore, Inc. announced the receipt of a new Federal Supply Schedule contract with the Veterans Affairs (VA), effective from June 15, 2025, to June 14, 2030, signaling a significant endorsement for its gammaCore device. The company noted an acceleration in revenue from VA hospitals in recent months following a minor slowdown. CEO Dan Goldberger remarked on the contract's importance in highlighting the value offered to veterans, especially in a challenging market landscape. The new contract includes standard provisions like prompt payment discounts, continuing their non-opioid pain solution offerings.
Read more →ECORelectroCore Announces Full Year 2024 Financial Results Record f ull year 2024 net sales of $ 25.2 million increased 57% over $ 16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCore TM in the Uni
electroCore announced a record full year 2024 revenue of $25.2 million, marking a 57% increase over 2023, driven by significant growth in Rx gammaCore and Truvaga sales. The company also reported a reduced net loss of $11.9 million, a 37% improvement from the prior year. Despite these positive results, the U.S. commercial sales of Rx gammaCore declined by 15%, and total operating expenses increased to approximately $33.6 million. The company remains focused on expanding market presence and achieving profitability in the upcoming years.
Read more →ECOR▼ -5.4%on this news
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025
electroCore, Inc. will announce its financial results for the fourth quarter and full year ended December 31, 2024, on March 12, 2025, after market close. The company, which specializes in bioelectronic medicine, will also host a webcast and conference call at 5:30 PM EDT for discussions on the results and to answer investor questions. This event underscores the company’s commitment to transparency and engagement with its stakeholders.
Read more →ECORelectroCore to Participate at Upcoming Investor Conferences
electroCore, Inc. announced its participation in two investor conferences in March 2025. The company will be represented by CFO Joshua Lev at both the 37th Annual Roth Conference and the LSI USA '25, held in Dana Point, California. This engagement aims to foster direct communication with potential investors and enhance visibility within the investment community.
Read more →ECORelectroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal
electroCore, Inc. has announced a partnership with Spark Biomedical, Inc. to distribute the Sparrow Ascent device for treating opioid withdrawal symptoms in Department of Veterans Affairs facilities. The Sparrow Ascent is an FDA-cleared, non-invasive neuromodulation device that offers a drug-free solution for veterans suffering from opioid withdrawal. This agreement allows electroCore to expand its therapeutic offerings while leveraging its distribution capabilities to improve access to the device among veterans. Both companies expressed optimism about the partnership's potential to aid recovery from addiction.
Read more →ECOR▲ +7.7%on this news
electroCore’s Truvaga™ Now Available on Amazon
electroCore, Inc. has announced that its flagship wellness product, Truvaga Plus, is now available for purchase on Amazon. Truvaga Plus is a handheld vagus nerve stimulator aimed at enhancing well-being by providing stress relief and improving focus. CEO Dan Goldberger noted that this availability on Amazon will help the product reach a broader audience. The company emphasizes its commitment to advancing health and wellness through their bioelectronic medicine technologies.
Read more →ECORelectroCore to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
electroCore, Inc. announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference scheduled for February 11-12, 2025, in Snowbird, Utah. CEO Dan Goldberger will be hosting one-on-one meetings with investors throughout the event, encouraging engagement with potential stakeholders. The company specializes in bioelectronic medicine and is focused on using its technology platform for medical and wellness solutions.
Read more →ECORelectroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness The Quell platform will strengthen our position
electroCore has entered into a definitive agreement to acquire NeuroMetrix, a move aimed at enhancing its presence in the bioelectronic medicine sector. The acquisition includes the Quell platform, which specializes in non-invasive treatments for conditions like fibromyalgia. The transaction is expected to close by the end of Q1 2025, subject to shareholder and regulatory approvals. electroCore anticipates that this acquisition will diversify its product offerings and significantly expand its addressable market.
Read more →ECORelectroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Award
electroCore, Inc. has announced that its product, Truvaga Plus, has won the Woman's World Magazine 50 over 50 Award. This award recognizes outstanding products for women over 50 based on quality, effectiveness, and value. CEO Dan Goldberger expressed pride in the recognition, emphasizing the product's benefits in enhancing quality of life through stress relief and improved mental clarity. Truvaga Plus is a vagus nerve stimulator designed for general wellness and is not intended to treat any diseases.
Read more →ECORelectroCore Donates gammaCore Sapphire for Real World Evaluation of nVNS in Trauma Among Israelis
electroCore, Inc. has donated 20 gammaCore Sapphire devices for a real-world evaluation of non-invasive vagus nerve stimulation (nVNS) in treating trauma among Israelis, led by Dr. Robin Ely and Dr. Yori Gidron. The initiative aims to address the serious impact of PTSD, particularly in veterans and active-duty military members. The collaboration emphasizes the need for novel therapeutic solutions in mental health. The evaluation signals electroCore's commitment to addressing critical health conditions using their pioneering technology.
Read more →ECORelectroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
electroCore, Inc. announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, scheduled for November 21, 2024, in New York City. CFO Joshua Lev will host one-on-one meetings with investors during the event. The forum is an opportunity for the company to enhance its visibility and discuss its non-invasive vagus nerve stimulation technology, which aims to improve health and wellbeing. Interested investors are encouraged to schedule meetings through their CG representative for further engagement.
Read more →ECOR▲ +7.8%on this news· ran to -22% by day 3shared move
electroCore Announces Third Quarter 2024 Financial Results Record quarterly revenues driven by 75% YoY growth of Rx gammaCore in the VA/DoD and 147% increase in Truvaga sales Company to host a conference call and webcast
electroCore, Inc. reported third-quarter 2024 financial results highlighting record revenues driven by substantial growth in their Rx gammaCore and Truvaga products. The company achieved a 45% increase in net sales year-over-year, totaling $6.6 million, alongside a significant reduction in net loss. Positive performance metrics indicate a successful trajectory for electroCore, with year-to-date revenues increasing by 67%. The management will discuss these results further in a conference call scheduled for later today.
Read more →ECOR▼ -6.8%on this news· ran to -18% by day 3shared move
ElectroCore’s Truvaga™ Plus Wins Men’s Health Magazine Tech Award
ElectroCore, Inc. announced that its wellness product, Truvaga Plus, received the Men’s Health Magazine Tech Award, highlighting its innovative contributions to men's health. The award recognizes products that significantly impact health and wellness, underscoring the value of Truvaga Plus in managing stress, enhancing sleep, and improving mental focus. CEO Dan Goldberger expressed pride in the recognition, reinforcing the company’s dedication to developing effective wellness solutions.
Read more →ECORelectroCore to Announce Third Quarter September 30, 2024 Financial Results on Wednesday, November 13, 2024
electroCore, Inc. has announced the schedule for its financial results for the third quarter ending September 30, 2024, which will be disclosed after market close on November 13, 2024. The company will hold a conference call and webcast at 4:30 PM EST to discuss these results and engage with stakeholders. As a bioelectronic medicine firm, electroCore focuses on non-invasive vagus nerve stimulation technologies for medical conditions and wellness.
Read more →ECOR▲ +5.8%on this newsshared move
electroCore Engages FNK IR to Execute Expanded Investor Relations Program
electroCore, Inc. has engaged FNK IR to enhance its investor relations program as part of its strategy to broaden outreach to potential investors. CEO Dan Goldberger highlighted the company’s strong financial trajectory, having reported record revenues for seven consecutive quarters and a five-year CAGR of 69%. With a focus on achieving positive cash flow early next year, the partnership with FNK IR is expected to increase investor awareness and drive sustained shareholder value. The company continues to emphasize its innovative bioelectronic medicine technologies aimed at improving health and wellness.
Read more →ECORelectroCore to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
electroCore, Inc. announced its participation in the 26th Annual H.C. Wainwright Global Investment Conference in New York City from September 9-11, 2024. CEO Dan Goldberger will be part of a fireside chat and is available for one-on-one meetings during the conference. The company focuses on non-invasive bioelectronic medicine, particularly through its vagus nerve stimulation technology platform. The announcement highlights electroCore's efforts to engage with investors and present its developments in the medical field.
Read more →ECORelectroCore Announces Second Quarter 2024 Financial Results Seventh consecutive record quarterly net sales of $ 6.1 million, an increase of 73% over second quarter 2023 Company to host a conference call and webcast today
electroCore, Inc. announced its financial results for Q2 2024, reporting record net sales of $6.1 million, a 73% increase from the same period in 2023. The company achieved a significant reduction in net loss, down 46% compared to last year. The launch of its new mobile app-enabled product, Truvaga Plus, and the commercial introduction of the TAC-STIM device were key developments. While the financial indicators demonstrate improvement, challenges persist in certain product segments, particularly TAC-STIM, which saw a significant drop in sales.
Read more →ECORelectroCore to Announce Second Quarter June 30, 2024 Financial Results on Wednesday, August 7, 2024
electroCore, Inc. has announced that it will report its financial results for the second quarter ending June 30, 2024, after market close on August 7, 2024. The company plans to host a conference call and webcast at 4:30 PM EDT to discuss the results and address queries. This reflects the ongoing operations and transparency of the company within the bioelectronic medicine sector.
Read more →ECORelectroCore, Inc. 200 Forge Way, Suite 205 Rockaway, NJ 07866
electroCore, Inc. has formalized an agreement with a board member concerning their transition from a Class III member to a Class I member. The member will serve as a consultant after July 11, 2024, with compensation set at $500 per hour and $3,000 per day for extended work. The company will also grant stock options that will vest during the consulting term. The agreement emphasizes the responsibilities and independence expected from the consultant's role.
Read more →ECORelectroCore Announces the Commercial Launch of TAC-STIM™
electroCore, Inc. has announced the commercial availability of TAC-STIM™, a non-invasive vagus nerve stimulator developed for active-duty military use. This portable device aims to enhance human performance by improving mood, cognitive capabilities, and reducing fatigue. TAC-STIM was developed in collaboration with the Air Force Research Laboratory and has shown positive results in independent testing. It is designed for wholesale purchases and is positioned as a low-risk wellness product.
Read more →ECORelectroCore to Join Russell Microcap Index
electroCore, Inc. announced its preliminary inclusion in the Russell Microcap Index, effective after the close of market on June 28, 2024. CFO Brian Posner expressed optimism that being added to the index could enhance the company’s visibility within the investment community. The Russell indexes are significant benchmarks for investment managers, with approximately $10.5 trillion in assets tracked against them. electroCore focuses on bioelectronic medicine and non-invasive therapies aimed at improving health and wellness.
Read more →ECORelectroCore, Inc. Announces Closing of $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
electroCore, Inc. has successfully closed a $9.3 million registered direct offering and concurrent private placements, which included pre-funded warrants and common stock warrants. The proceeds will be used for sales and marketing, working capital, and general corporate purposes. The CEO highlighted strong revenue momentum for the company, indicating confidence in sustaining operations until cash flow becomes positive in 2025. The offerings were priced at market under Nasdaq rules, reflecting investor interest in the company's future prospects.
Read more →ECORelectroCore, Inc. Announces $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules ROCKAWAY, NJ
electroCore, Inc. has announced a $9.3 million registered direct offering and concurrent private placements to institutional accredited investors. This includes pre-funded warrants and shares of common stock priced at market rates under Nasdaq rules. The company plans to use the net proceeds for sales and marketing, working capital, and other corporate purposes. The transactions are expected to close by June 5, 2024, subject to customary conditions.
Read more →ECORelectroCore Announces First Quarter 2024 Financial Results Record first quarter 2024 net sales of $ 5.4 million, an increase of 96% over first quarter 2023 Company to host a conference call and webcast today
electroCore, Inc. has reported its first quarter 2024 financial results, showcasing record net sales of $5.4 million, a 96% increase compared to the same period in 2023. The gross profit was reported at $4.6 million, maintaining a gross margin of 84%. However, the company continues to incur a net loss of $3.5 million, which, while lower than the previous year's loss, reflects ongoing operational challenges. electroCore will host a conference call to discuss these results further.
Read more →ECORelectroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024
electroCore, Inc. has announced that it will report its financial results for the first quarter ending March 31, 2024, on May 8, 2024, after the market closes. The company will hold a conference call and webcast at 4:30 PM EDT to discuss these results and address any questions from stakeholders. electroCore specializes in bioelectronic medicine focusing on non-invasive vagus nerve stimulation technology.
Read more →ECORelectroCore Announces the Launch of Truvaga Plus for General Wellness
electroCore, Inc. announced the launch of Truvaga Plus, a new mobile app-enabled product aimed at enhancing general wellness. Available for purchase on April 8, 2024, through the company's eCommerce platform, Truvaga Plus builds upon the success of Truvaga 350, offering features such as unlimited usage sessions, a rechargeable design, and mobile app connectivity. The product is positioned as a holistic and convenient solution for managing stress and improving overall well-being, leveraging non-invasive vagus nerve stimulation technology. Truvaga Plus is intended for general health purposes and does not claim to diagnose or treat medical conditions.
Read more →ECORelectroCore Announces Fourth Quarter and Full Year 2023 Financial Results Record f ull year 2023 net sales of $ 16.0 million increased 87% over $ 8.6 million for the full year 2022 Company to host conference call and web
electroCore, Inc. reported strong financial results for the fourth quarter and full year of 2023, highlighted by record net sales of $16.0 million, an 87% increase year-over-year. The fourth quarter alone saw revenues increasing by approximately 103% compared to the same period in 2022, driven largely by increased sales of gammaCore medical devices and wellness products. Despite these positive results, the company registered a GAAP net loss of $18.8 million, although it was an improvement from the previous year's loss. The company plans to discuss these results in a conference call with investors.
Read more →ECORelectroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024
electroCore, Inc. announced that it will release its financial results for the fourth quarter and the year ending December 31, 2023, on March 13, 2024. The announcement follows the close of the market and will be followed by a conference call at 4:30 PM EST where management will discuss the results and field investor questions. The company's commitment to bioelectronic medicine and wellness reflects its dedication to healthcare innovation through non-invasive technologies.
Read more →ECORelectroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology
electroCore, Inc. has announced the issuance of a new patent by the United States Patent and Trademark Office for a system designed to stimulate nerve targets in the head and neck for treating various conditions including primary headaches. This patent, numbered 11,839,764, covers a downloadable software program that manages the electrical stimulation of the nerves through a mobile device. The Chief Strategy Officer highlighted this achievement as part of the company's efforts to expand its intellectual property portfolio and develop next-generation application-enabled products.
Read more →ECORelectroCore Announces Third Quarter 2023 Financial Results Record third quarter 2023 net sales of $ 4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year
electroCore, Inc. reported a robust third quarter for 2023, achieving net sales of $4.5 million, which reflects a significant 128% increase compared to $2.0 million in the same quarter of 2022. The company has raised its full year revenue guidance to between $15.0 million and $15.5 million, indicating strong growth prospects. Additionally, electroCore successfully raised approximately $7.5 million in funding from institutional investors. However, despite the positive growth in sales, the company reported a GAAP net loss of $4.0 million, though this is an improvement from the prior year's loss.
Read more →ECOR▼ -6.2%on this newsshared move
electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
electroCore, Inc. has announced that its CEO, Dan Goldberger, will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 16, 2023. The event will be held at the Westin NY Grand Central, where electroCore will also facilitate 1x1 investor meetings. The company specializes in bioelectronic medicine, particularly using non-invasive vagus nerve stimulation to enhance wellbeing.
Read more →ECORelectroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue
electroCore, Inc. announced a two-year extension for its gammaCore device in the NHS Supply Chain catalogue, now valid until March 17, 2026. This extension, initially set to expire in March 2024, is seen as a significant move to enhance patient access to non-invasive vagus nerve stimulation therapy across the UK. The company emphasized the increased validation and potential benefits of the gammaCore therapy for patients suffering from migraines and cluster headaches. The announcement was made on October 17, 2023, highlighting electroCore's commitment to expanding its market presence in the UK.
Read more →ECORelectroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
electroCore, Inc. announced the issuance of U.S. Patent No. 11,779,756 by the United States Patent and Trademark Office, which pertains to a new treatment protocol for non-invasive vagus nerve stimulation (nVNS). This patent emphasizes a treatment approach that involves a specified duration and frequency of stimulation. The company's CEO highlighted the importance of this patent in strengthening their position in the bioelectronic medicine market. Overall, this development showcases electroCore's ongoing commitment to advancing its innovative non-invasive therapy solutions.
Read more →ECORelectroCore to Announce Third Quarter Financial Results on Wednesday, November 8
electroCore, Inc. is set to announce its third quarter financial results on November 8, 2023, after market close. The company, known for its bioelectronic medicine technology, will host a conference call at 4:30 PM EST to discuss the results and address any investor questions. This announcement highlights the company's ongoing commitment to transparency and investor communication.
Read more →ECORelectroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference
electroCore, Inc. will participate in the Lytham Partners Fall 2023 Investor Conference on October 17, 2023. CEO Dan Goldberger will be available for virtual one-on-one meetings with investors. This event aims to strengthen investor relations and promote the company's bioelectronic medicine offerings. The participation underscores electroCore's commitment to improving health through its non-invasive vagus nerve stimulation technology.
Read more →ECORelectroCore to Participate in the LD Micro Main Event XVI Conference
electroCore, Inc. announced that its CEO, Dan Goldberger, will present at the LD Micro Main Event XVI Conference occurring from October 3 to 5, 2023, in Los Angeles, California. This event aims to enhance the company's visibility in the investor community. electroCore is known for its bioelectronic medicine technology, focusing on non-invasive vagus nerve stimulation for health management.
Read more →ECORelectroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference
electroCore, Inc. announced that CEO Dan Goldberger will present at iAccess Alpha's virtual conference themed 'Top 10 Best Ideas from the Buyside'. The presentation is scheduled for September 26, 2023, and Goldberger will also be available for one-on-one meetings during the event. The company specializes in bioelectronic medicine, specifically using non-invasive vagus nerve stimulation technology for health improvement and wellness.
Read more →ECORelectroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
electroCore, Inc. announced that its CEO, Dan Goldberger, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The event is scheduled for September 11, 2023, and will include a recorded presentation starting at 7:00 am ET. electroCore is a bioelectronic medicine company focused on utilizing non-invasive vagus nerve stimulation technology for health improvement and consumer wellness. This participation is seen as an opportunity for exposure and potential growth within the industry.
Read more →ECORelectroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering
electroCore, Inc. announced the complete dismissal of all litigation related to its 2018 initial public offering, resulting in a full vindication of the company. The federal court concluded that the plaintiffs did not adequately plead any allegations of wrongdoing. The ruling followed previous dismissals in both federal and state courts, affirming that electroCore did not mislead investors. With the legal matters resolved, electroCore can now concentrate on advancing its business and product development initiatives.
Read more →ECOR▼ -10.1%on this news
electroCore Announces Second Quarter 2023 Financial Results Record second quarter 2023 net sales of $ 3.6 million, an increase of approximately 65% over second quarter 2022 Company to host a conference call and webcast t
electroCore, Inc. reported significant financial growth in the second quarter of 2023, achieving net sales of $3.6 million, a notable 65% increase from the previous year. The company announced the selection of its TAC-STIM technology for a U.S. Air Force research project and reported positive findings on gammaCore's impact on PTSD. Despite the strong revenue growth, electroCore continues to face challenges with a GAAP net loss of $4.9 million and rising operating expenses. The company has raised approximately $7.5 million through new funding efforts to support its ongoing operations.
Read more →ECORelectroCore to Announce Second Quarter Financial Results on Wednesday, August 9
electroCore, Inc. has announced they will release their second quarter financial results for the period ending June 30, 2023, on August 9, 2023. Following the release, management will conduct a conference call and webcast at 4:30 PM EDT to discuss the results and answer questions. This announcement showcases the company’s commitment to transparency and stakeholder communication as it operates in the bioelectronic medicine sector.
Read more →ECORelectroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules ROCKAWAY, NJ
electroCore, Inc. has announced an $8.145 million fundraising initiative through a registered direct offering and concurrent private placements. The transaction involves selling 1,675,914 shares of common stock and warrants to institutional investors, along with shares for the company's officers and directors. The proceeds are intended for sales and marketing efforts, working capital, and general corporate purposes. The offerings are set to close around August 2, 2023, pending customary closing conditions.
Read more →ECORelectroCore Expands Intellectual Patent Portfolio for nVNS Technology
electroCore, Inc. announced the issuance of a new patent by the USPTO for its non-invasive vagus nerve stimulation technology, specifically for a system utilizing mobile devices. This patent, numbered 11,701,515, is part of electroCore's ongoing strategy to expand its intellectual property portfolio, which now exceeds 200 patents and applications. The company plans to leverage this innovation in future product developments aimed at enhancing health and wellness.
Read more →ECORelectroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC
electroCore, Inc. has announced a distribution agreement with Reliefband Technologies to provide the Reletex device, which is the first FDA-cleared non-invasive neuromodulation device for nausea and vomiting. ElectroCore will exclusively distribute this product within the Department of Veterans Affairs and other Federal Supply Schedule entities. Both companies expressed optimism about the collaboration, aiming to deliver non-drug treatment solutions to veterans suffering from nausea. The agreement highlights electroCore's strategy to enhance its commercial offerings and meet patient needs with innovative technology.
Read more →ECORelectroCore Provides Select Second Quarter 2023 Financial Guidance
electroCore, Inc. has announced its preliminary unaudited financial guidance for Q2 2023, forecasting record revenues of approximately $3,550,000, representing a 65% increase from the previous year. The company reports expected revenues from government channels, cash pay prescriptions, and its newly launched products, with growth in prescriber numbers. However, it notes a decrease in revenues from international markets and a net cash outflow during the quarter. The company maintains its full-year revenue guidance of $14.0-$15.0 million.
Read more →ECORelectroCore Provides Select Second Quarter 2023 Financial Guidance Record revenue of approximately $3,550,000 for the three months ended
electroCore, Inc. has released preliminary financial guidance for the second quarter of 2023, indicating record revenue of approximately $3,550,000, a notable 65% increase from the same quarter in 2022. Revenue from the government's channel, which includes the Department of Veterans Affairs and Department of Defense, sees a promising 75% growth. The company maintains its full-year revenue guidance between $14.0 and $15.0 million, with an operational update expected during their August earnings call.
Read more →ECORelectroCore to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC
electroCore, Inc. announced its participation in the Healthcare Virtual Conference Part II, scheduled for June 21, 2023. CEO Dan Goldberger will present at the event hosted by Maxim Group LLC and M-Vest. The company, specializing in bioelectronic medicine and wellness, aims to improve health using its non-invasive vagus nerve stimulation technology. The conference represents a strategic opportunity for electroCore to connect with potential investors and stakeholders in the healthcare sector.
Read more →ECOR▲ +7.8%on this newsshared move
electroCore Announces Poster to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
electroCore, Inc. announced that a poster titled 'SUNCT/SUNA with neurovascular conflict: consider nVNS' will be presented at the American Headache Society’s 65th Annual Scientific Meeting on June 16-17, 2023. The poster will detail a retrospective study showcasing the efficacy of non-invasive vagus nerve stimulation (nVNS) in patients with rare headache disorders. The findings suggest that nVNS should be considered before opting for costly and risky microvascular neurosurgery.
Read more →ECOR▼ -5.5%on this news
electroCore, Inc. Announces Departure of JP Errico from the Board of Directors
electroCore, Inc. has announced the resignation of its Founder and former CEO, JP Errico, from the Board of Directors, although he will remain as a consultant and strategic advisor. The company's CEO emphasized Errico's continued contribution to their wellness and human performance brands. The Board Chairman acknowledged Errico’s significant prior contributions to the company, particularly in the development of non-invasive vagus nerve stimulation technology. As electroCore looks to expand its offerings, Errico's ongoing involvement in advising the company is seen as a positive continuation of his legacy.
Read more →ECORelectroCore to Participate at 13th Annual LD Micro Invitational XIII
electroCore, Inc. announced that CEO Dan Goldberger will present at the 13th Annual LD Micro Invitational XIII in Los Angeles from June 6-8, 2023. The event will be livestreamed for virtual viewers. electroCore is focused on the commercialization of medical devices based on their non-invasive vagus nerve stimulation technology to improve health and wellbeing. This participation showcases the company's commitment to innovation and engagement within the bioelectronic medicine industry.
Read more →ECOR▼ -7.7%on this newsshared move
electroCore, Inc. Rockaway, NJ
electroCore, Inc. has entered into a new agreement with Mr. Joseph P. Errico to serve as a consultant, titled Science and Strategic Advisor. This agreement, effective from February 1, 2020, guarantees Errico a monthly retainer of $10,000 for a minimum of 20 hours of consultation. The agreement also allows for additional paid hours if approved by the CEO, with specified rates for such extra hours. The term of the agreement lasts until May 22, 2026, unless mutually extended.
Read more →ECORelectroCore Announces First Quarter 2023 Financial Results Record first quarter 2023 net sales of $ 2.8 million, approximately 46% over first quarter 2022 Company to host a conference call and webcast today
electroCore, Inc. reported first quarter 2023 financial results, achieving record net sales of $2.8 million, marking a 46% increase compared to the same period last year. The company highlighted strong marketing efforts for its wellness product Truvaga and shared encouraging study results on its gammaCore therapy. Despite the growth in sales, electroCore recorded a net loss of $5.9 million, slightly higher than the prior year's loss, while operating expenses also rose. The company reiterated its revenue guidance for the year and expects cash usage to decrease as revenues grow.
Read more →ECORelectroCore to Participate at Annual Aegis Virtual Conference
electroCore, Inc. has announced that its CEO, Dan Goldberger, will present at the Annual Aegis Virtual Conference scheduled for May 2-4, 2023. The company specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation (nVNS) technology. The conference represents an opportunity for electroCore to enhance its visibility and engage with industry stakeholders. The company aims to improve health management through its innovative medical devices and consumer products.
Read more →ECORelectroCore to Announce First Quarter Financial Results on Wednesday, May 3
electroCore, Inc. will announce its first-quarter financial results for the period ended March 31, 2023, on May 3, 2023, following the market close. A conference call and webcast will be hosted by management at 4:30 PM EDT to discuss the results and address any stakeholder questions. The company specializes in non-invasive vagus nerve stimulation technology, aiming to enhance health through its medical devices and consumer products.
Read more →ECOR▲ +9.5%on this newsshared move
electroCore Provides Select First Quarter 2023 Financial Guidance
electroCore, Inc. announced preliminary financial guidance for Q1 2023, projecting record revenue of approximately $2.8 million, marking a 46% increase compared to Q1 2022. The company expects $1.8 million in revenue from government channels and approximately $581,000 from U.S. commercial sales, including $147,000 from its recently launched Truvaga. International revenue is also anticipated to increase significantly. For FY 2023, electroCore reiterates its revenue guidance of $14.0-$15.0 million, attributing growth to existing channels and new products.
Read more →ECORelectroCore Announces Remittance of Annual License Fee from Teijin for Certain Exclusive Rights in Japan
electroCore, Inc. has announced that Teijin Limited has remitted its annual license fee to extend its exclusive rights to electroCore's non-invasive vagus nerve stimulation (nVNS) technology for commercialization in Japan. The license agreement includes an upfront payment and milestone payments related to commercializing the product for various headache disorders. Teijin will oversee all regulatory approval costs and has expressed strong commitment to the partnership and the commercialization efforts in Japan. The agreement enhances the potential market for gammaCore's nVNS technology within the Japanese healthcare system.
Read more →ECORelectroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa
electroCore, Inc. has announced the receipt of product registration for their non-invasive vagus nerve stimulator, gammaCore Sapphire™, in Indonesia, Malaysia, and South Africa. This marks the first registrations for the company in both the Far East and African continent, enhancing their global footprint. The approvals are expected to increase access for patients and support the launch of the product through local distributors who have strong networks in these regions. With a combined population of 367 million, these new markets are seen as a significant opportunity for commercial growth.
Read more →ECORelectroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute
electroCore, Inc. has announced that its gammaCore Sapphire™ non-invasive vagus nerve stimulator will now be available for purchase by clinicians through the Carrick Institute for Graduate Studies. This partnership aims to enhance clinician education on functional neurology and increase patient access to the gammaCore device, which is utilized for the treatment of migraine and cluster headache. The Carrick Institute has a strong reputation in clinical neuroscience education, having trained over 19,000 scholars. This collaboration represents a significant step in making the therapy accessible to more patients suffering from primary headaches.
Read more →ECORelectroCore Provides Select First Quarter 2023 Financial Guidance Record revenue of approximately $2.8M expected for the three months ended
electroCore, Inc. has announced its preliminary unaudited financial guidance for the first quarter of 2023, expecting record revenues of approximately $2.8 million, representing a 46% increase compared to Q1 2022. Key contributors to this growth include a robust $1.8 million from government channels, particularly the Department of Veterans Affairs and the Department of Defense, as well as a substantial rise in commercial sales. Additionally, the company maintains its overall revenue guidance for 2023 at $14.0-$15.0 million. The announcement emphasizes the positive trajectory of the company's revenue streams and ongoing expansion efforts.
Read more →ECOR▲ +17.1%on this news· ran to +46% by day 1
electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
electroCore, Inc. announced the publication of a study demonstrating that non-invasive vagus nerve stimulation (nVNS) significantly improves outcomes in a rat model of traumatic brain injury (TBI). The study, appearing in the Journal of Neurotrauma, reported reductions in brain lesion volume and improved neurobehavioral assessments following nVNS treatment. The findings suggest that nVNS could represent a novel therapeutic approach for TBI, a condition with limited treatment options. Further investigation into nVNS's efficacy on TBI will be supported by a grant from the National Institute of Neurological Disorders and Stroke.
Read more →ECOR▲ +6.5%on this news· ran to +64% by day 3shared move
electroCore's Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study
electroCore, Inc. announced positive results from a recent focus group study of their Truvaga product, which is designed for wellness through vagus nerve stimulation. Participants used the device for 30 days and reported improvements in mood, anxiety, stress, energy, and sleep. Specifically, 91% indicated their mood had improved, and 88% felt less anxious. Following the study, a substantial majority of users expressed intentions to continue using Truvaga for ongoing wellness benefits.
Read more →ECORelectroCore Affirms No Direct Exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank
electroCore, Inc. confirmed it does not have direct exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank, ensuring its financial stability amidst recent banking sector turmoil. The company emphasizes that it holds corporate cash accounts with larger, more stable global banks. electroCore specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation technologies for health improvement. This announcement may offer reassurance to investors regarding the company's current financial position and operational focus.
Read more →ECORelectroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting
electroCore, Inc. (Nasdaq: ECOR) announced that it will present data from a study on its nVNS technology at the 2023 American Academy of Neurology Annual Scientific Meeting. The study focuses on the ability of transcutaneous cervical vagus nerve stimulation to enhance second language vocabulary acquisition while aiding cognitive function. The poster presentation is scheduled for April 23, 2023, in Boston. The announcement highlights electroCore's ongoing efforts to advance its nVNS technology for various applications.
Read more →ECOR▲ +9.5%on this newsshared move
electroCore to Participate at 35th Annual Roth Conference
electroCore, Inc. has announced its participation in the 35th Annual Roth Conference scheduled for March 12-14, 2023, in Dana Point, California. Chief Strategy Officer Joshua Lev will engage in a fireside chat during the event. The company also offers opportunities for one-on-one meetings with investors. electroCore focuses on commercializing its non-invasive vagus nerve stimulation technology for health management and wellness.
Read more →ECOR▲ +6.6%on this news· ran to +17% by day 1shared move
electroCore Announces Fourth Quarter and Full Year 2022 Financial Results Record f ull year 202 2 net sales of $ 8.6 million increased 5 8 % over $ 5 . 5 million for full year 202 1 Company to host conference call and we
electroCore, Inc. announced its financial results for the fourth quarter and full year of 2022, highlighting record net sales of $8.6 million, reflecting a 58% growth from the previous year. The fourth quarter alone saw a 72% increase in sales, driven by the successful launch of two new wellness brands. Despite the financial gains, the company reported a GAAP net loss of $22.2 million and increased operating expenses. Looking ahead, electroCore projects net revenue for 2023 to be between $14.0 and $15.0 million, driven partly by growth in legacy headache channels and new product revenues.
Read more →ECORelectroCore Regains Compliance with Nasdaq Listing Requirements
electroCore, Inc. has announced that it regained compliance with Nasdaq's minimum bid price requirement, indicating positive momentum for the company. The stock price exceeded $1.00 per share for ten consecutive trading days, allowing it to remain listed on the Nasdaq Capital Market. This compliance is essential for maintaining investor interest and shows progress in its business activities involving bioelectronic medicine and wellness.
Read more →ECOR▼ -6.6%on this news
electroCore to Announce Fourth Quarter and Year Ended December 31, 2022 Financial Results on Wednesday, March 8
electroCore, Inc. will release its financial results for the fourth quarter and full year ending December 31, 2022, on March 8, 2023. The announcement includes a conference call and webcast for stakeholders to discuss the results. The company specializes in bioelectronic medicine, specifically through its non-invasive vagus nerve stimulation technology. This engagement indicates the company's intention to maintain transparency with investors and the public.
Read more →ECOR▼ -12%on this news
electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa
electroCore, Inc. announced an exclusive distribution agreement with Byond Healthcare Pty Ltd to distribute its gammaCore SapphireTM device in South Africa and Namibia. This partnership aims to enhance the accessibility of non-invasive vagus nerve stimulation (nVNS) technology for patients suffering from headache-related pain. The agreement is initially set for three years and is consistent with Byond's mission to provide innovative pain management solutions in the region. The gammaCore device is FDA-cleared and CE-marked for several headache treatments, emphasizing its clinical validity and potential impact on local healthcare.
Read more →ECORelectroCore Completes Sale of New Jersey Tax Benefits
electroCore, Inc. has completed the sale of its tax benefits through New Jersey's Technology Business Tax Certificate Transfer program, receiving approximately $211,000 in non-dilutive cash. This funding will support the company as it continues to grow and develop its business. Over three years, electroCore has benefited from around $2.7 million in non-dilutive financing from the State of New Jersey, which has played a significant role in facilitating its operations and growth objectives.
Read more →ECOR▼ -19.9%on this newsshared move
electroCore Announces Reverse Stock Split
electroCore, Inc. announced a reverse stock split at a ratio of 1-for-15, effective February 15, 2023. This decision, approved by stockholders, is aimed at boosting the share price to comply with Nasdaq's minimum bid price rule. While the reverse stock split allows shareholders to maintain their ownership percentage, there is no certainty it will ensure continued listing on Nasdaq, as the company awaits the outcomes of its appeal process. Despite these challenges, electroCore is also focusing on its bioelectronic medicine technology platform to drive future growth.
Read more →ECOR▼ -19.9%on this newsshared move
electroCore Announces Reverse Stock Split ROCKAWAY, N.J.
electroCore, Inc. announced a reverse stock split of its shares at a ratio of 1-for-15, effective February 15, 2023. This decision follows stockholder approval to amend the company's certificate of incorporation, aiming to increase the market price of its shares and maintain compliance with Nasdaq listing requirements. The company has appealed recent determinations regarding its compliance status and plans to implement this stock split as part of its strategy to avoid delisting.
Read more →ECOR▲ +25.3%on this news
electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update
electroCore, Inc. has announced a record revenue of approximately $2.5 million for Q4 2022 and a total revenue of $8.5 million for the full year, reflecting a growth of 57% compared to 2021. The company reported successful launches of two new products aimed at addressing stress and wellness. However, its cash reserves decreased at year-end, which may impact future operations. electroCore plans to provide a detailed operational update in March 2023.
Read more →ECORelectroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update Record revenue of approximately $2.5 million for the three months ended
electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update ROCKAWAY, N.J., January 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the "Company") (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited pr
Read more →ECOR▼ -6.3%on this news
electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™
ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called TruvagaTM for customers residing in the United States. The new wellness product is of
Read more →ECOR▼ -18.5%on this news
electroCore Announces Issuance of Two New U.S. Patents
ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents related to its non-invasive vagus nerve stimula
Read more →ECOR▼ -7.7%on this news· ran to +32% by day 3
electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be conducting one-on-ones at the Canaccord Genuity MedTech and D
Read more →ECOR▲ +16.6%on this news
electroCore Announces Third Quarter 2022 Financial Results Third quarter 2022 revenue grew 33% over third quarter 2021 Company to host a conference call and webcast today
electroCore Announces Third Quarter 2022 Financial Results Third quarter 2022 revenue grew 33% over third quarter 2021 Company to host a conference call and webcast today, November 3, 2022 at 4:30 pm EDT ROCKAWAY, NJ, Nov. 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq
Read more →ECOR▲ +13.3%on this newsshared move
electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC
ROCKAWAY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pai
Read more →ECORelectroCore to Announce Third Quarter 2022 Financial Results on November 3
ROCKAWAY, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the third quarter ended September 30, 2022, after the close of the market on Thursday,
Read more →ECORelectroCore Provides Select Third Quarter 2022 Financial Guidance
ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the third quarter of 2022. Preliminary unaudited financial gu
Read more →ECORelectroCore Provides Select Third Quarter 2022 Financial Guidance Revenue will be approximately $2.0 million; roughly 33% growth over third quarter 2021
electroCore Provides Select Third Quarter 2022 Financial Guidance ROCKAWAY, N.J., October 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the "Company") (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial gui
Read more →ECORelectroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents
ROCKAWAY, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued four patents related to its non-invasive vagus nerve stimu
Read more →ECORElectrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals
ROCKAWAY, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine company, today announced its plans to hold its fiscal year 2022 annual meeting of stockholders (the “2022 Annual Meeting”) on Friday, De
Read more →ECORDATED SEPTEMBER 20, 2022 ELECTROCORE ANNOUNCES DATE FOR FISCAL YEAR 2022
ELECTROCORE ANNOUNCES DATE FOR FISCAL YEAR 2022 ANNUAL MEETING AND DEADLINES FOR STOCKHOLDER PROPOSALS ROCKAWAY, N.J., September 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the "Company"), a commercial-stage bioelectronic medicine company, today announced it
Read more →ECOR▼ -7.5%on this news
electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be presenting at the Canaccord Genuity 42nd Annual Growth Confer
Read more →ECORelectroCore Announces Record Second Quarter 2022 Financial Results Record second quarter 2022 net sales of $ 2.2 million, increased 70% over second quarter 2021 and 14% sequentially Company to host a conference call and
electroCore Announces Record Second Quarter 2022 Financial Results Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and 14% sequentially Company to host a conference call and webcast today, August 4, 2022 at 4:30 pm EDT ROCKAWAY, NJ,
Read more →ECOR▲ +5%on this news
electroCore to Announce Second Quarter 2022 Financial Results on August 4
ROCKAWAY, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the second quarter ended June 30, 2022, after the close of the market on Thursday, Augu
Read more →ECORelectroCore Provides Select Second Quarter 2022 Financial Guidance
Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021 June 30, 2022, cash and cash equivalents balance of approximately $26.6 million ROCKAWAY, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a
Read more →ECORelectroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome
ROCKAWAY, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an investigator-initiated study to assess the efficacy of gammaCore Sapphire non-invasive vagus nerve s
Read more →ECORelectroCore Provides Select Second Quarter 2022 Financial Guidance Record r evenue will be at least $2.1 million; approximately 65% growth over second quarter 2021
electroCore Provides Select Second Quarter 2022 Financial Guidance ROCKAWAY, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the "Company") (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guida
Read more →ECORelectroCore Announces Listing Transfer to the Nasdaq Capital Market ROCKAWAY, N.J.
electroCore Announces Listing Transfer to the Nasdaq Capital Market ROCKAWAY, N.J., June 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the "Company") (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has received approval from the Na
Read more →ECOR▼ -6.5%on this news
electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers
ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more th
Read more →ECORelectroCore Announces Record First Quarter 2022 Financial Results First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially Company to host a conference call and webcast
electroCore Announces Record First Quarter 2022 Financial Results First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially Company to host a conference call and webcast today, May 5, 2022 at 4:30 pm EDT ROCKAWAY, NJ, May 5, 2
Read more →ECOR▼ -12.3%on this news
electroCore to Announce First Quarter 2022 Financial Results on May 5
ROCKAWAY, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2022, after the close of the market on Thursday, May
Read more →ECORelectroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology
ROCKAWAY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published results from an investigator-initiated trial, SAVIOR-1, a prospective, randomized, con
Read more →ECORelectroCore Provides Business Update and Select First Quarter 2022 Financial Guidance
Record revenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021 March 31, 2022, cash balance of approximately $29.9M ROCKAWAY, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial
Read more →ECORelectroCore Announces Exclusive License Agreement with Teijin for Japan Territory
ROCKAWAY, N.J., April 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with Teijin Limited (Teijin), a global conglomerate based in Japan offering ad
Read more →ECORelectroCore Provides Business Update and Select First Quarter 2022 Financial Guidance Record r evenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021
electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance ROCKAWAY, NJ, April 12, 2022 -- electroCore, Inc. (the "Company") (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as
Read more →ECORelectroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York
ROCKAWAY, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced its co-founder and Chief Medical Officer, Dr. Peter Staats, will keynote the Fifth Annual Bioelectronic Medicin
Read more →ECOR▲ +6.2%on this newsshared move
electroCore to Present at 2022 Maxim Virtual Growth Conference
ROCKAWAY, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be presenting at the 2022 Maxim Virtual Growth
Read more →ECORelectroCore Announces Fourth Quarter and Full Year 2021 Financial Results Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020 Ended 2021 with cash and cash equivalent
electroCore Announces Fourth Quarter and Full Year 2021 Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020 Ended 2021 with cash and cash equivalents Company to host conference call and webcast today, March 10, 2022, at 4
Read more →ECORelectroCore Announces Changes to its Board of Directors Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding significant marketing, media and brand strategy experience ROCKAWAY, N.J.
electroCore Announces Changes to its Board of Directors Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding significant marketing, media and brand strategy experience ROCKAWAY, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commer
Read more →ECORelectroCore to Present at 34th Annual Roth Conference
ROCKAWAY, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be presenting at the 34th Annual Roth Conference. Details for access to the prese
Read more →ECORelectroCore to Announce Fourth Quarter and Year Ended December 31, 2021 Financial Results on Thursday, March 10
ROCKAWAY, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the fourth quarter and year ended December 31, 2021, after the close of the market on
Read more →ECORelectroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus
ROCKAWAY, N.J., Feb. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced enrollment has been completed for the TRANSIT study of non-invasive vagal nerve stimulation (nVNS) to reduce ileus after colorect
Read more →ECORelectroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022
ROCKAWAY, N.J., Jan. 25, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced three abstracts focusing on the possible mechanistic or clinical role of nVNS for the acute treatment of stroke will be presented
Read more →ECOR▲ +8.3%on this news· ran to -19% by day 3
electroCore Announces Shareholder Letter and Full-Year 2021 Business Update Company anticipates full-year 2021 revenue of approximately $5.5 million, an approximately 55% increase over full-year 2020 ROCKAWAY, NJ
electroCore Announces Shareholder Letter and Full-Year 2021 Business Update Company anticipates full-year 2021 revenue of approximately $5.5 million, an approximately 55% increase over full-year 2020 ROCKAWAY, NJ, Jan. 18, 2022 -- electroCore, Inc. (Nasdaq: ECOR) today publi
Read more →ECORelectroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store
ROCKAWAY, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients residing in the United States. The site, which can be accessed through www.gammacor
Read more →ECORelectroCore Announces Publication of PREMIUM II Trial of gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine
ROCKAWAY, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled “Non-invasive vagus nerve stimulation for prevention of migraine: The multicen
Read more →ECORelectroCore to Present at H.C. Wainwright BIOCONNECT Virtual Conference
ROCKAWAY, NJ, Jan. 04, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The confer
Read more →ECORelectroCore, Inc. Provides Update on Global Distribution Partners
ROCKAWAY, NJ, Dec. 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into agreements with Melidonia Health Services (Melidonia), Cyrus Medical Technologies (Cyrus), and
Read more →ECORelectroCore, Inc. Announces The Launch of a New Online Shop in the United Kingdom
ROCKAWAY, NJ, Dec. 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients residing in the United Kingdom. The site, which can be found at www.
Read more →ECOR▼ -5.8%on this newsshared move
electroCore, Inc. Provides Update on nVNS to Treat Post Traumatic Stress Disorder
ROCKAWAY, NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on the ongoing clinical research to assess the potential of gammaCore (non-invasive vagal nerve stimulat
Read more →ECORelectroCore Announces New Patent for Stroke and TIA Treatment
ROCKAWAY, NJ, Dec. 13, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,191,953 to the Company, r
Read more →ECORelectroCore to Participate at Canaccord Genuity MedTech & Diagnostics Forum
ROCKAWAY, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be available for virtual one-on-one meetings at the Canaccord Genuity MedTech & Diag
Read more →ECORelectroCore Announces Third Quarter 2021 Financial Results Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020 Company to host a conference call and webcast today
Announces Third Quarter 2021 Financial Results Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020 Company to host a conference call and webcast today, November 4, 2021 at 4:30 pm ET ROCKAWAY, NJ, November 4, 2021 (GLOBE NEWSWIRE) -- electroCore,
Read more →ECORelectroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th
ROCKAWAY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2021 after the close of the market on Thursday, November
Read more →ECORelectroCore Announces Publication Reviewing the Prescribing of gammaCore for the Treatment of Cluster Headache in England
ROCKAWAY, NJ, Oct. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper entitled “Non-invasive vagus nerve stimulation for treatment of cluster headache: a retros
Read more →ECORelectroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine
ROCKAWAY, NJ, Oct. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that the company received an amended Medical Device License from Health Canada to expand the label of gammaCore nVNS to include the
Read more →ECORelectroCore Provides Business Update and Select Third Quarter 2021 Financial Guidance Third quarter 2021 revenue expected to be approximately $1.5 million Net cash used to fund operations in the third quarter 2021 of app
Provides Business Update and Select Third Quarter 2021 Financial Guidance ROCKAWAY, NJ, October 12, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select u
Read more →ECORelectroCore Announces Acceptance of Motion to Dismiss in the Federal Court Securities Class Action Suit
ROCKAWAY, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced the granting of the company’s motion to dismiss the federal court securities class action case filed in Trenton, NJ. On August 13, 2021,
Read more →ECORelectroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference
ROCKAWAY, NJ, Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference has been rescheduled to today
Read more →ECORelectroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
ROCKAWAY, NJ, Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the SAVIOR-1 study; a prospective, randomized, controlled study evaluating non-invasive v
Read more →ECORelectroCore Announces Peter Cuneo as Board Chairman ROCKAWAY, NJ
electroCore Announces Peter Cuneo as Board ROCKAWAY, NJ, September 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Board of Directors has appointed Peter Cuneo as Chairman of the Board o
Read more →ECORelectroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices
ROCKAWAY, NJ, Sept. 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, syste
Read more →ECOR▼ -5.9%on this newsshared move
electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua
ROCKAWAY, NJ, Sept. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that on September 10, 2021 the company received Section 510(k) clearance from the United States Food and Drug Administration (FDA
Read more →ECORelectroCore to Present at the HC Wainwright 23rd Annual Global Investment Conference
ROCKAWAY, NJ, Aug. 31, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the HC Wainwright 23rd Annual Global Investment Con
Read more →ECOR▲ +7.2%on this news
electroCore Announces New Reseller Agreement with Red One Medical Devices, LLC.
ROCKAWAY, NJ, Aug. 24, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a reseller agreement with Red One Medical Devices, LLC. (Red One). The partnership will further expand availability of electroCore’
Read more →ECORelectroCore Announces Second Quarter 2021 Financial Results Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequentially Company to host a conference call and webcast today
electroCore Announces Second Quarter 2021 Financial Results Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequentially Company to host a conference call and webcast today, August 5, 2021 at 4:30 pm ET ROCKAWAY, N.J., August 05,
Read more →ECORelectroCore Announces Publication in PharmacoEconomics Reiterating Economic Benefits of gammaCore for Cluster Headache Outlined by The National Institute for Health and Care Excellence (NICE) Medical Technologies Guidance
ROCKAWAY, NJ, Aug. 04, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company (the Company), today announced the release of an article entitled “gammaCore for Cluster Headaches: A NICE Medical Technologies Guidance” in the jou
Read more →ECORelectroCore to Present at the Canaccord Genuity Growth Conference
ROCKAWAY, NJ, Aug. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation and be available for virtual one-on-one meetings at th
Read more →ECORelectroCore Announces Issuance of New Patent for Migraine Treatment using Smartphones
ROCKAWAY, NJ, July 27, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,065,444 to electroCore, relating to the u
Read more →ECORelectroCore to Announce Second Quarter 2021 Financial Results on Thursday, August 5th
ROCKAWAY, NJ, July 22, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2021 after the close of the market on Thursday, August 5, 202
Read more →ECORelectroCore announces Dr. Peter Staats to receive Lifetime Achievement Award from the American Society of Pain and Neuroscience
ROCKAWAY, NJ, July 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical Officer, Dr. Peter Staats, is to receive a Lifetime Achievement Award at the
Read more →ECORelectroCore Provides Business Update and Select Second Quarter 2021 Financial Guidance
Second-Quarter 2021 revenue expected to be approximately $1.3 million Net cash used to fund operations in the second quarter 2021 of approximately $3.2 million Follow on offering subsequent to June 30, 2021 added $18.8 million to cash balance ROCKAWAY, NJ, July 13, 2021 (GLOBE
Read more →ECORelectroCore to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
ROCKAWAY, NJ, July 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, CEO will present a company overview and be available for 1x1 meetings at the following upcoming conference: L
Read more →ECORelectroCore Announces Pricing of $18.0 Million Public Offering of Common Stock ROCKAWAY, NJ
electroCore Announces Pricing of $18.0 Million Public Offering of ROCKAWAY, NJ, June 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the "Company"), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the pricing of an underwritten public offerin
Read more →ECORelectroCore Announces Proposed Public Offering of Common Stock
ROCKAWAY, NJ, June 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All the shares to
Read more →ECORelectroCore Announces Publication of Study on the Effect of non-invasive Vagus Nerve Stimulation (nVNS) on Cognitive Performance Caused by Sleep Deprivation
ROCKAWAY, NJ, June 24, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper on June 10, 2021, entitled “Effects of Transcutaneous Vagal Nerve Stimulation (tVNS/nVNS)
Read more →ECORelectroCore, Inc. Announces Exclusive Distribution Agreement with Kromax For Taiwan and China
ROCKAWAY, NJ, June 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with Kromax International Corporation to serve as the exclusive distributor of the gammaCore Sapph
Read more →ECORelectroCore Completes Sale of $1.4 Million of NJ NOL Tax Benefits
ROCKAWAY, NJ, June 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of $1.4 million of its available tax benefits through the New Jersey Economic Development Authority’
Read more →ECORelectroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’s Disease Patients
ROCKAWAY, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled “Non-Invasive Vagus Nerve Stimulation Improves Clinical and Molecular Biomarke
Read more →ECORelectroCore to Present at Investor Conferences in June
ROCKAWAY, NJ, May 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several investor conferences during the month of June. The conferencing details are as follo
Read more →ECORelectroCore Announces First Quarter 2021 Financial Results Record First quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020 and 30% sequentially Company to host a conference call and webcast tod
electroCore Announces First Quarter 2021 Financial Record First quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020 and 30% sequentially Company to host a conference call and webcast today, May 6, 2021 at 4:30 pm ET May 6, 2021 at 4:05 pm ET ROCKAW
Read more →ECORelectroCore, Inc. Announces U.S. Department of Veterans Affairs Study of gammaCore Sapphire™ (Non-Invasive Vagus Nerve Stimulator) for the Treatment of Post-Traumatic Headache
ROCKAWAY, NJ, May 04, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the U.S. Department of Veterans Affairs is starting an investigator-initiated study of the use of gammaCore SapphireTM non-invasi
Read more →ECORelectroCore to Announce First Quarter 2021 Financial Results on Thursday, May 6
ROCKAWAY, NJ, April 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2021 after the close of the market on Thursday, May 6, 2021.
Read more →ECORelectroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders
ROCKAWAY, NJ, April 26, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Johns Hopkins University School of Medicine is starting an investigator-initiated trial of non-invasive vagus nerve stimu
Read more →ECORelectroCore, Inc. Announces Exclusive Distribution Agreement with East Agency For Qatar
ROCKAWAY, NJ, April 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with East Agency to serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive v
Read more →ECORelectroCore Announces Publication in Nature Reviews: Neurology Highlighting the Role of Non-Invasive Vagus Nerve Stimulation (nVNS) as an Emerging Treatment for Cluster Headache
ROCKAWAY, NJ, April 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Cluster headache pathophysiology — insights from current and emerging treatments,” by Drs.
Read more →ECORelectroCore Provides Business Update and Select First Quarter 2021 Financial Guidance First quarter 2021 revenue expected to be more than $1.1 million Net cash used for the first quarter 2021 of approximately $4.1 millio
electroCore Provides Business Update and Select First Quarter 2021 Financial Guidance 2021 revenue expected to be more than $1.1 million for the first quarter 2021 of approximately $4.1 million April 13, 2021 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectron
Read more →ECORelectroCore Announces Top Line Results from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
ROCKAWAY, NJ, April 08, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the top-line results from the SAVIOR-1 study, a prospective, randomized, controlled study evaluating non-invasive vagus nerve stim
Read more →ECORelectroCore, Inc. Announces Regulatory Approval in Canada
ROCKAWAY, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Health Canada has granted regulatory approval for the promotion and sale of the gammaCore Sapphire family of products in Can
Read more →ECORelectroCore, Inc. Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa. For Western Europe
ROCKAWAY, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with Silvert Medical Nv-Sa. (“Silvert Medical”) whereby Silvert Medical will serve as the exclu
Read more →ECORelectroCore Announces Fourth Quarter and Full Year 2020 Financial Results Full year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year 2019 Further reduced net cash usage to $3.7 m
Announces Fourth Quarter and Full Year 2020 Financial Results year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year 2019 reduced net cash usage to $3.7 million in the fourth quarter 2020 versus $4.1 million in the third quarter 2020 20
Read more →ECORelectroCore to Announce Fourth Quarter and Year Ended December 31, 2020 Financial Results on Thursday, March 11
ROCKAWAY, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth quarter and year ended December 31, 2020 after the close of the market on Thursda
Read more →ECORelectroCore to Participate at Two Upcoming Investor Conferences
ROCKAWAY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in two upcoming investor conferences. H.C. Wainwright Global Life Sciences Conference Format:
Read more →ECORelectroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia
ROCKAWAY, N.J., Feb. 28, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Medistar2 PTY Limited (“Medistar”) whereby Medistar will serve as the exclusive distri
Read more →ECORelectroCore Announces Two-Year Extension of gammaCore™ Listing in the NHS Supply Chain Catalogue
ROCKAWAY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore will continue to be listed in the NHS Supply Chain catalogue for an additional two years through June 3, 2023. The
Read more →ECORelectroCore Announces 510(k) Clearance of gammaCore TM Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine FDA clearance expands gammaCore label to include the acute and preventive treatment of migra
Announces 510(k) Clearance of gammaCoreTM Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine FDA clearance expands gammaCore label to include the acute and preventive treatment of migraine in adolescents 12 to 17 years of age ROCKAWAY, N.J., February 16,
Read more →ECORelectroCore Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting Respiratory Symptoms
ROCKAWAY, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the completion of patient enrollment in SAVIOR-1, a prospective, randomized, controlled study evaluating vagus nerve stimulation
Read more →ECORelectroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Reduce Ileus After Major Colorectal Surgery
ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major colorectal
Read more →ECORelectroCore to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
ROCKAWAY, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools
Read more →ECORelectroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke
ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatm
Read more →ECORelectroCore, Inc. Announces Inclusion of gammaCore Sapphire™ in new NHS England and NHS Improvement MedTech Funding Mandate Policy 2021/22
ROCKAWAY, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire (nVNS) has been included in a new long-term reimbursement policy launched by Matthew Whitty, Director of
Read more →ECORelectroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada
ROCKAWAY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with RSK Medical Inc. (“RSK Medical”) whereby RSK Medical will serve as the exclusive distr
Read more →ECORelectroCore, Inc. Announces Scottish Health Technology Group Recommendation For Use of gammaCore™ in NHS Scotland Cluster Headache Patients
ROCKAWAY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland (“HIS”) has published a Scottish Health Technology Group (“SHTG”) adaptation for NHS Scotland on
Read more →ECORelectroCore, Inc. Announces the Establishment of a Unique Level II HCPCS Code for "Non-Invasive Vagus Nerve Stimulator" ROCKAWAY, N.J.
Inc. Announces the Establishment of a Unique Level II HCPCS Code for "Non-Invasive Vagus Nerve Stimulator" ROCKAWAY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Centers for Me
Read more →ECORelectroCore Provides Business Update and Select Financial Guidance
Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M; greater than 40% growth over full year 2019 revenue of $2.4M Net cash used for the fourth quarter 2020 of $3.7 million, compares favorably to previously announced guidance o
Read more →ECORelectroCore Provides Business Update and Select Financial Guidance Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M; greater than 40% growth over full year 2019 rev
electroCore Provides Business Update and Select Financial Guidance Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M; greater than 40% growth over full year 2019 revenue of $2.4M Net cash used for the fourth quarter 2020
Read more →ECORelectroCore, Inc. Announces Agreement with Pro Medical Baltic to be Exclusive Distributor for gammaCore Sapphire™ in Eastern Europe
ROCKAWAY, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Pro Medical Baltic UAB (“PMB”), whereby PMB will serve as the exclusive distributor of
Read more →ECORelectroCore Announces Positive Top-Line Results from PREMIUM II Migraine Prevention Study
BASKING RIDGE, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today top-line results from its GM-US-10 (PREMIUM II) study. Despite the early termination of the study in April 2020 due to the C
Read more →ECORelectroCore to Present at the 13th Annual LD Micro Main Event Conference
BASKING RIDGE, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management is scheduled to present at the 13th Annual LD Micro Main Event Conference. Presentation details: Date: Mon
Read more →ECORelectroCore Announces Selection of gammaCore for National Institute on Drug Abuse (NIDA)-Sponsored Study in Opioid Use Disorders
BASKING RIDGE, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that its gammaCore non-invasive vagus nerve stimulator (nVNS) has been selected for evaluation in a randomized controlled st
Read more →ECORelectroCore to Participate in Upcoming Virtual Investor Conferences
BASKING RIDGE, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will participate in two upcoming in
Read more →ECORelectroCore Announces Third Quarter Financial Results Revenue growth of 44% over the second quarter of 2020 and 58% over the third quarter of 2019 Return to sequential revenue growth across all channels Further strengthe
electroCore Announces Third Quarter Financial Results Revenue growth of 44% over the second quarter of 2020 and 58% over the third quarter of 2019 Return to sequential revenue growth across Further strengthened balance sheet Reduced quarterly cash burn Company to host conf
Read more →ECORelectroCore to Announce Third Quarter Ended September 30, 2020 Financial Results on Thursday, November 12
BASKING RIDGE, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2020 after the close of the market on Thursday, No
Read more →ECORelectroCore, Inc. Appoints Business Development Leader and US Navy Veteran Sylvester Steele as VP and General Manager of Government Channels Business Unit
BASKING RIDGE, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Sylvester “Sly” Steele to the newly created position of Vice President and General Manager of the Governm
Read more →ECORelectroCore Provides Business Update and Select Financial Guidance Third quarter 2020 Revenue expected to exceed $1 million, representing an increase of greater than 35% sequentially and greater than 50% over Q3 2019 Ope
electroCore Provides Business Update and Select Financial Guidance Third quarter 2020 Revenue expected to exceed $1 million, representing an increase of greater than 35% sequentially and greater than 50% over Q3 2019 Operating cash burn for the third quarter 2020 of approxim
Read more →ECORelectroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in England
ITP program providing reimbursement for gammaCore™ extended to March. 31, 2021 with option for additional three years The potential contract value if the three-year extension option is exercised could be up to approximately £3.6 million (or approximately $4.6 million based on th
Read more →ECORelectroCore Announces Department of Veterans Affairs Sponsored Study of Non-Invasive Vagal Nerve Stimulation (nVNS) in Mild Traumatic Brain Injury (mTBI) and Post-Traumatic Stress Disorder (PTSD)
BASKING RIDGE, N.J., Sept. 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Department of Veterans Affairs has agreed to sponsor a quadruple blind, randomized, sham-controlled clinical trial
Read more →ECORelectroCore Announces Agreement with UpScript, LLC to be Exclusive Online Telehealth Provider for gammaCore Sapphire™ CV
BASKING RIDGE, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into exclusive agreement with UpScript, LLC in which UpScript will serve as the exclusive online telehe
Read more →ECORelectroCore to Participate in the JMP Securities MedTech Bio Summit
BASKING RIDGE, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, chief executive officer, will participate in a fireside chat at the JMP Securities MedTech Bio Summit,
Read more →ECORelectroCore to Present at the HC Wainwright Virtual 22nd Annual Global Investment Conference
BASKING RIDGE, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management is scheduled to present at the HC Wainwright Virtual 22nd Annual Global Investment Conference, which is bei
Read more →ECORelectroCore Announces Publication in Brain Stimulation Highlighting Non-Invasive Vagal Nerve Stimulation’s (nVNS) Potential Role in Treatment of Post-Traumatic Stress Disorder (PTSD)
BASKING RIDGE, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts1,
Read more →ECORelectroCore, Inc. Announces Publication of a Voluntary ex-ante Transparency Tender Notice Award by NHS England to Fund Continued Use of gammaCore™ in England
BASKING RIDGE, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Official Journal of the European Union (OJEU) has published a Voluntary ex-ante Transparency Tender Notice on behal
Read more →ECORelectroCore Announces Second Quarter Financial Results Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected COVID-19 patients experiencing asthma exacerbations Generated se
electroCore Announces Second Quarter Financial Results Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected COVID-19 patients experiencing asthma exacerbations Generated sequential increase in revenue Further strengthened balan
Read more →ECORelectroCore to Announce Second Quarter Ended June 30, 2020 Financial Results on Thursday, August 13
BASKING RIDGE, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2020 after the close of the market on Thursday, August
Read more →ECORelectroCore Provides Update on Availability of gammaCore Sapphire CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients Initial distribution to hospitals and patients expected to begi
Provides Update on Availability of gammaCore Sapphire CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected Initial distribution to hospitals and patients expected to begin on July 31st BASKING RIDGE, N.J., July 30, 2020 -- electroCore, Inc. (Nasdaq: ECOR),
Read more →ECORelectroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia
BASKING RIDGE, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Non-invasive vagus nerve stimulation for primary headache: a clinical update,”1 in Ce
Read more →ECORelectroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients Intended use allows gamaCore Sapphire CV use
electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Intended use allows gamaCore Sapphire CV use at home or in a healthcare setting BASKING RIDGE, N.J., July 13,
Read more →ECORelectroCore to Participate in Three Upcoming Virtual Investor Conferences
BASKING RIDGE, N.J., July 09, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger, Chief Executive Officer, will participate in three upcoming investor conferences: Maxim Group/M-Vest C
Read more →ECORelectroCore, Inc. to Present at Little Grapevine’s G1 Microcap Virtual Conference
BASKING RIDGE, N.J., May 29, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger, Chief Executive Officer, will be available at Little G
Read more →ECORelectroCore Announces First Quarter Financial Results Generated first quarter revenue of $734,000 Secured FDA clearance of gammaCore (nVNS) label expansion for migraine prevention Announced initiatives to support the pot
electroCore Announces First Quarter Financial Results Generated first quarter revenue of $734,000 Secured FDA clearance of gammaCore (nVNS) label expansion for migraine Announced initiatives to support the potential use of nVNS for the treatment of symptoms associated with COV
Read more →ECORelectroCore to Announce First Quarter Ended March 31, 2020 Financial Results on Thursday, May 14
BASKING RIDGE, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2020 after the close of the market on Thursday, May 14,
Read more →ECORelectroCore Provides Update on COVID-19 Clinical Initiatives Randomized controlled investigator-initiated trial (IIT) of non-invasive vagus nerve stimulation (nVNS) therapy currently enrolling COVID-19 patients in Spain
electroCore Provides Update on COVID-19 Clinical Initiatives Randomized controlled investigator-initiated trial (IIT) of non-invasive vagus nerve stimulation therapy currently enrolling COVID-19 patients in Spain Peer-reviewed paper, Use of Non-Invasive Vagus Nerve Stimulation
Read more →ECORelectroCore Provides Business Update and Select First Quarter 2020 Guidance
electroCore Provides Business Update and Select First Quarter 2020 Guidance RIDGE, N.J., April 17, 2020 electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance fo
Read more →ECORelectroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in the U.K.
BASKING RIDGE, N.J., April 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP)
Read more →ECORelectroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19
electroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19 BASKING RIDGE, N.J., April 2, 2020 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medici
Read more →ECORelectroCore Announces 510(k) Clearance of gammaCore™ Label Expansion into Migraine Prevention
BASKING RIDGE, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has received Section 510(k) clearance from the U.S. Food and Drug Administration (FDA) of the company’s su
Read more →ECORelectroCore Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital
BASKING RIDGE, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into a common stock purchase agreement of up to $25 million with Lincoln Park Capital Fund, LLC (“Linco
Read more →ECORelectroCore Announces Changes to its Board of Directors John Gandolfo, Tom Patton and Peter Cuneo to join the Board, adding significant medical technology operational, financial and turn-around experience
electroCore Announces Changes to its Board of Directors John Gandolfo, Tom Patton and Peter Cuneo to join the Board, adding significant medical technology operational, financial and turn-around experience BASKING RIDGE, N.J., March 26, 2020 electroCore, Inc. (Nasdaq: ECOR), a
Read more →ECORelectroCore Announces Fourth Quarter and Full Year 2019 Financial Results Continued growth in VA and U.K. Channels Company to host conference call and webcast today
electroCore Announces Fourth Quarter and Full Year 2019 Financial Results Continued growth in VA and U.K. Channels Company to host conference call and webcast today, March 23, 2020 at 4:45 pm ET March 23, 2020 at 4:05 PM EST BASKING RIDGE, N.J., March 23, 2020 electroCore, I
Read more →ECORelectroCore Announces Fourth Quarter and Full Year 2019 Financial Results
Continued growth in VA and U.K. Channels Company to host conference call and webcast today, March 23, 2020 at 4:45 pm ET BASKING RIDGE, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced
Read more →ECORelectroCore to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 23
BASKING RIDGE, N.J., March 19, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth quarter and year ended December 31, 2019 after the close of the market on Mo
Read more →ECORelectroCore, Inc. Announces Rebate Agreement with Ascent Health Services for gammaCore Preferred Brand Coverage on all Express Scripts Standard National Formularies
BASKING RIDGE, N.J., Jan. 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Ascent Health Services on behalf of Express Scripts, one of the nation’s leading pharmacy benefit managers (PBMs) headq
Read more →ECORelectroCore Announces Board of Directors Transition
electroCore Announces Board of Directors Transition BASKING RIDGE, N.J., December 27, 2019 electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company s current Chairman of the Board, Carrie S. Cox, will resign from the
Read more →ECORelectroCore to Present at the Two December Investor Conferences
BASKING RIDGE, N.J., Nov. 26, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, Chief Executive Officer, will present a corporate overview and host investor meetings at the Evercore
Read more →ECORto the Company's Form 8-K furnished with the SEC on
A Commercial-Stage Bioelectronic Medicine Company Nasdaq: ECOR Corporate Presentation November 2019 Exhibit 99.1 Forward Looking Statement In addition to historical information, this presentation may contain forward-looking statements with respect to our business, capital reso
Read more →ECORelectroCore Announces Third Quarter 2019 Financial Results Continued growth in prescribing physicians, paid months of therapy and dispensed prescriptions Company to host conference call and webcast today, November 13, at
electroCore Announces Third Quarter 2019 Financial Results Continued growth in prescribing physicians, paid months of therapy and dispensed prescriptions Company to host conference call and webcast today, November 13, at 4:30pm ET November 13, 2019 at 4:05 PM EST BASKING RIDG
Read more →ECORelectroCore to Announce Third Quarter 2019 Financial Results on Wednesday, November 13th
BASKING RIDGE, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter and nine-months ended September 30, 2019 after the close of the market
Read more →ECORELECTROCORE, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for District of New Jersey on behalf of all investors that purchased electroCore, Inc.
NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all investors that purchased electroCore,
Read more →ECORelectroCore Appoints Medical Technology Veteran Daniel S. Goldberger as Chief Executive Officer
BASKING RIDGE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Daniel S. Goldberger as Chief Executive Officer, effective October 1. Mr. Goldberger brings to electroCo
Read more →ECORelectroCore Provides Update on 510(k) Submission Seeking Expanded Indication for gammaCore Additional information requested by FDA; Premium 2 trial progressing as planned
electroCore Provides Update on 510(k) Submission Seeking Expanded Indication for gammaCore Additional information requested by FDA; Premium 2 trial progressing as September 25, 2019 at 8:00am ET RIDGE, N.J., September 25, 2019 electroCore, Inc. (Nasdaq: ECOR, or the Company ),
Read more →ECORelectroCore Announces Second Quarter 2019 Financial Results Sequential growth reported in paid months of therapy, prescribing physicians and prescriptions dispensed Company to host conference call and webcast today, Augu
electroCore Announces Second Quarter 2019 Financial Results Sequential growth reported in paid months of therapy, prescribing physicians and prescriptions dispensed Company to host conference call and webcast today, August 13, at 4:30pm ET August 13, 2019 at 4:05 PM EST BASKI
Read more →ECORelectroCore Announces Distribution Agreement with Doctor’s Medical LLC to Expand Patient Access to gammaCore
BASKING RIDGE, N.J., Aug. 12, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the company has entered into an exclusive contract with Doctor’s Medical, LLC for distribution rights to gammaCore for patie
Read more →ECORelectroCore to Announce Second Quarter 2019 Financial Results on Tuesday, August 13
BASKING RIDGE, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter and six-months ended June 30, 2019 after the close of the market on T
Read more →ECORelectroCore Files Registration Statement on Form S-3
electroCore Files Registration Statement on Form S-3 July 15, 2019 at 4:30 pm ET BASKING RIDGE, N.J., July 15, 2019 electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has filed a universal shelf registration statement o
Read more →ECORELECTROCORE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In electroCore, Inc. To Contact The Firm
NEW YORK, July 11, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against electroCore, Inc. (“electroCore” or the “Company”) (NASDAQ: ECOR). If you invested in electroCore stock or options and would like t
Read more →ECORelectroCore Announces gammaCore(TM) Listing on the NHS Supply Chain Catalogue
LONDON, and BASKING RIDGE, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCoreTM, the company’s non-invasive vagus nerve stimulator (nVNS), will appear on the N
Read more →ECORSEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (this Agreement ) is entered into by and between Francis A Amato ( Executive ) and electroCore, Inc., a Delaware corporation (the Company ) (when col
SEPARATION AND RELEASE AGREEMENT Separation and Release Agreement (this Agreement ) is entered into by and between Francis A Amato ( Executive ) and electroCore, Inc., a Delaware corporation (the Company ) (when collectively referenced herein, Executive and the Company shall be
Read more →ECORelectroCore Announces Frank R. Amato to Step Down as Chief Executive Officer
BASKING RIDGE, N.J., June 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frank R. Amato will be stepping down as Chief Executive Officer. Mr. Amato joined electroCore in 2012 and was named Chi
Read more →ECORSEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (this Agreement ) is entered into by and between Joseph P. Errico ( Executive ) and electroCore, Inc., a Delaware corporation (the Company ) (when co
SEPARATION AND RELEASE AGREEMENT Separation and Release Agreement (this Agreement ) is entered into by and between Joseph P. Errico ( Executive ) and electroCore, Inc., a Delaware corporation (the Company ) (when collectively referenced herein, Executive and the Company shall b
Read more →ECORDisclaimers This presentation contains "forward-looking" statements. These statements identify substantial risks and uncertainties and relate to future events such as execution of our strategy or our future financial per
Annual Meeting of Shareholders 06/07/2019 Exhibit 99.1 Disclaimers This presentation contains "forward-looking" statements. These statements identify substantial risks and uncertainties and relate to future events such as execution of our strategy or our future financial perfo
Read more →ECORelectroCore Announces Comprehensive Redeployment and Cost Reduction Plan Management to host conference call and webcast at 8:30 am ET on Thursday, May 30
electroCore Announces Comprehensive Redeployment and Cost Reduction Plan Management to host conference call and webcast at 8:30 am ET on Thursday, May 30 May 29, 2019 at 4:30 p.m. EDT BASKING RIDGE, N.J., May 29, 2019 electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioel
Read more →ECORelectroCore Announces First Quarter 2019 Financial Results Continues to deliver sequential growth in covered lives, prescribing physicians and FSS facilities Company to host conference call and webcast today, May 14, at
electroCore Announces First Quarter 2019 Financial Results Continues to deliver sequential growth in covered lives, prescribing physicians and FSS facilities Company to host conference call and webcast today, May 14, at 4:30pm ET May 14, 2019 at 4:05 PM EST BASKING RIDGE, N.J
Read more →ECORelectroCore to Announce First Quarter 2019 Financial Results on Tuesday, May 14
BASKING RIDGE, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report first quarter ended March 31, 2019 financial results after the close of the market on Tuesday May 14, 2019. Ma
Read more →ECORelectroCore Selected for Innovation and Technology Payment Program Through NHS England
LONDON and BASKING RIDGE, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore, the company’s non-invasive vagus nerve stimulator (nVNS), has been selected throug
Read more →ECORelectroCore Announces Fourth Quarter and Full Year 2018 Financial Results Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018 Company to host conference call and webcast today, March 27, at 4
electroCore Announces Fourth Quarter and Full Year 2018 Financial Results Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018 Company to host conference call and webcast today, March 27, at 4:30pm ET March 27, 2019 at 4:05 PM EST BASKING RIDGE, N.
Read more →ECORelectroCore to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Wednesday, March 27
BASKING RIDGE, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it will report fourth quarter and year ended December 31, 2018 financial results after the close of the market on Wedn
Read more →ECORelectroCore Announces Encouraging Research Supporting Key Areas of Clinical Development for its Non-Invasive Vagus Nerve Stimulator, gammaCore™
BASKING RIDGE, N.J., March 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a global commercial-stage bioelectronic medicine company, today announced new preclinical and clinical research supporting the potential therapeutic benefit of its non-invasive vagus nerve s
Read more →ECORelectroCore Appointments Multiple Industry Veterans to Key Management Positions
BASKING RIDGE, N.J., March 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointments of Dr. Tony Fiorino as chief medical officer and Brian Posner as chief financial officer. The company’s cu
Read more →ECORelectroCore Announces Positive Coverage Policies of gammaCore Issued by Highmark
BASKING RIDGE, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Highmark, one of the nation’s top health insurers and the third largest Blue Cross Blue Shield affiliated company, has
Read more →ECORelectroCore and HealthyWomen Announce Partnership on Patient Program to Increase Awareness of Non-Drug Migraine Therapies
BASKING RIDGE, N.J. and NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a patient education initiative in partnership with HealthyWomen, the nation’s leading independent, nonprofit he
Read more →ECORelectroCore to Present at Noble Capital Markets’ Fifteenth Annual Investor Conference
BASKING RIDGE, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced Chief Executive Officer, Frank Amato and Chief Science & Strategy Officer, JP Errico will present at NobleCon
Read more →ECORelectroCore Announces Two New Studies and a Publication Supporting the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults
BASKING RIDGE, N.J., Jan. 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced two clinical studies focused on expanding the use of non-invasive vagus nerve stimulation (nVNS) for the acute and preventiv
Read more →ECORCommercial-Stage Bioelectronic Medicine Company Corporate Presentation January 2019 Disclaimer In addition to historical information, this presentation may contain forward-looking statements with respect to our business,
Commercial-Stage Bioelectronic Medicine Company Corporate Presentation January 2019 Disclaimer In addition to historical information, this presentation may contain forward-looking statements with respect to our business, capital resources, strategy and growth reflecting the cur
Read more →ECORelectroCore Receives FDA Clearance for gammaCore™ (nVNS) for Adjunctive Use for the Preventive Treatment of Cluster Headache in Adults
BASKING RIDGE, N.J., Nov. 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an expanded label for gammaCore™ [non
Read more →ECORelectroCore Recieves FDA Clearance for gammaCore (nVNS) for Adjunctive Use for the Preventive Treatment of Cluster Headache in Adults Basking Ridge, NJ
electroCore Recieves FDA Clearance for gammaCore (nVNS) for Adjunctive Use for the Preventive Treatment of Cluster Headache in Adults Basking Ridge, NJ, November 28, 2018 - electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that
Read more →ECORelectroCore Expands Manufacturing Capabilities for gammaCore™
BASKING RIDGE, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced expansion into a new design and development facility to support increasing patient demand of its gammaCore™ n
Read more →ECORelectroCore, Inc. to Present at the Evercore ISI HealthCONx Conference
BASKING RIDGE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the company will be participating in the upcoming Evercore ISI HealthCONx Conference in Boston, MA. electro
Read more →ECORelectroCore, Inc. Announces Third Quarter Financial Results
electroCore, Inc. Announces Third Quarter Financial Results BASKING RIDGE, NJ, November 13, 2018 - electroCore, Inc. ("electroCore") (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today reported financial results for the three months and nine months ended Sep
Read more →ECORelectroCore, Inc. to Report Third Quarter Financial Results on November 13, 2018
BASKING RIDGE, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it will release financial results for the third quarter ended September 30, 2018 after the close of tra
Read more →ECORelectroCore, Inc. Announces Appointment of Ardelle Ferris as Vice President of Managed Care
BASKING RIDGE, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Ardelle Ferris to a new position within the company, Vice President of Managed Care. Ardel
Read more →ECORelectroCore, Inc. to Present at the Cantor Global Healthcare Conference
BASKING RIDGE, N.J., Sept. 18, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced the company will be participating in the upcoming Cantor Global Healthcare Conference in New York, NY. elec
Read more →ECORelectroCore to Present Additional Research for Non-invasive Vagus Nerve Stimulation in Headache Disorders at the 17th Biennial Migraine Trust International Symposium
BASKING RIDGE, N.J., Sept. 05, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that seven abstracts and an oral presentation featuring non-invasive vagus nerve stimulation (nVNS) across two primary head
Read more →ECORelectroCore, Inc. Announces Second Quarter Financial Results
electroCore, Inc. Announces Second Quarter Financial Results BASKING RIDGE, NJ, August 13, 2018 - electroCore, Inc. ("electroCore") (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today reported financial results for the three month and six months ended June 3
Read more →ECORelectroCore, Inc. Announces Research Collaboration with Massachusetts General Hospital to Explore Non-Invasive Vagus Nerve Stimulation in Neuroinflammation
BASKING RIDGE, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a research collaboration with Massachusetts General Hospital (MGH) through the company’s funding of a MGH program targeting
Read more →ECORelectroCore, Inc. to Report Second Quarter Financial Results on August 13, 2018
BASKING RIDGE, N.J., July 26, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced that it will release financial results for the second quarter 2018 after the close of trading on Monday, Augu
Read more →ECORelectroCore and UpScript Launch Program to Offer Direct-to-Patient Telemedicine Option for gammaCore™ in the United States
BASKING RIDGE, N.J., July 17, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, announced today a program with UpScript, a digital healthcare platform, offering a direct-to-patient telemedicine option for gammaCore™ non-i
Read more →ECORelectroCore, Inc. Announces Additions to Board of Directors in Connection with Recently Completed Initial Public Offering
BASKING RIDGE, N.J., July 10, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Carrie S. Cox as Chairman of its Board of Directors, and Michael G. Atieh and Stephen L. O
Read more →ECORelectroCore to Present Additional Research for Non-invasive Vagus Nerve Stimulation (nVNS) in Headache Disorders at the 60th Annual Meeting of the American Headache Society
BASKING RIDGE, N.J., June 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, announced today it will present six abstracts across three primary headache disorders at the 60th Annual Meeting of the American Headache Soc
Read more →ECORelectroCore, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
BASKING RIDGE, N.J., June 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR) today announced that the underwriters of its previously announced initial public offering of common stock have exercised in full their option to purchase an additional 780,000 s
Read more →ECORelectroCore, Inc. Announces Closing of Initial Public Offering
BASKING RIDGE, N.J., June 26, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR) today announced the closing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $15.00 per share. The proceeds from this offering, n
Read more →ECORelectroCore, Inc. Announces Pricing of Initial Public Offering
BASKING RIDGE, N.J., June 21, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) today announced the pricing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $15.00 per share. All of the shares of common stock are being offe
Read more →Competitive Position
How ECOR ranks across every disease it competes inCompetitive Position is a premium feature
See how ECOR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial